Related Experiment Videos
New data in treatment of acute coronary syndromes
1Department of Cardiology, Gasthuisberg University Hospital, Leuven, Belgium. Fans.VandeWerf@uz.kuleuven.ac.be
Insights
New anticoagulants like Org31540/SR90107A show promise for acute coronary syndromes (ACS). This Factor Xa inhibitor has demonstrated positive outcomes in ST-elevation myocardial infarction, with ongoing evaluations for other ACS types.
Area of Science:
- Cardiology
- Pharmacology
- Thrombosis
Background:
- Anticoagulants are crucial for acute coronary syndromes (ACS) management.
- Unfractionated heparin (UHF) improves outcomes in ACS without ST-segment elevation and may benefit fibrinolytic therapy.
- Standard heparin's unpredictable effects and bleeding risks necessitate novel anticoagulant development.
Purpose of the Study:
- To evaluate the clinical relevance of new anticoagulants in ACS patients.
- To assess the efficacy and safety of Org31540/SR90107A, a novel synthetic pentasaccharide and selective Factor Xa inhibitor.
Main Methods:
- Investigated new anticoagulants including direct antithrombins, low-molecular-weight heparins, and anti-Factor Xa agents in ACS.
- Conducted the PENTALYSE trial with over 300 patients with ST-segment elevation acute myocardial infarction.
- Initiated the PENTUA trial comparing Org31540/SR90107A with enoxaparin in ACS patients.
Main Results:
- Org31540/SR90107A demonstrated promising results in patients with ST-segment elevation acute myocardial infarction (PENTALYSE trial).
- Ongoing PENTUA trial is evaluating Org31540/SR90107A against enoxaparin in a broader ACS population.
Conclusions:
- Org31540/SR90107A shows potential as an effective anticoagulant in ACS with ST-segment elevation.
- Further research is needed to determine the efficacy of Org31540/SR90107A in ACS without ST-segment elevation.
Background:
Anticoagulants are important in the treatment of acute coronary syndromes (ACS). When given in combination with aspirin, unfractionated heparin (UHF) improves the clinical outcome in patients who have ACS without ST-segment elevation. UHF also has potential benefits when administered in conjunction with fibrinolytic agents, especially those that are fibrin-specific. The anticoagulant effect of standard heparin is unpredictable, and excessive bleeding complications have been observed in nearly all trials.
Methods:
New anticoagulants, including direct antithrombins, low-molecular-weight heparins, and more recently, agents with a pure anti-Factor Xa effect, have been tested in patients with ACS and found to have varying degrees of clinical relevance.
Results:
One new synthetic pentasaccharide, Org31540/SR90107A, an antithrombin III-binding selective inhibitor of Factor Xa, has been studied in more than 300 patients with acute myocardial infarction with ST-segment elevation (PENTALYSE trial). In an ongoing trial (PENTUA), Org31540/SR90107A is being compared with enoxaparin in patients with ACS, with and without ST-segment elevation.
Conclusions:
Org31540/SR90107A has shown promising results in ACS with ST-segment elevation. Efficacy in ACS without ST-segment elevation is currently under evaluation.